Advertisement
Home Day 5

Day 5

video

bb21217 Shows Encouraging Efficacy, Safety, and CAR T-Cell Expansion

Noopur Raje, MD, director of the multiple myeloma program at Massachusetts General Hospital, discusses the safety and efficacy results of the CRB-402...

Combination of Venetoclax, Obinutuzumab, and Atezolizumab Shows Promise in Richter’s Transformation

According to results presented at the 2021 American Society of Hematology Annual Meeting, patients with previously untreated Richter’s transformation (RT) had high...

MRD-Guided Ibrutinib Combination Successful in Relapsed/Refractory Chronic Lymphocytic Leukemia

Research presented at the 2021 ASH Annual Meeting suggests that patients with relapsed/refractory chronic lymphocytic leukemia (CLL) suggests that measurable residual disease...

Evaluating Adoptive Immunotherapy to Prevent Acute GVHD

Adoptive immunotherapy with CD4+/CD25/+FOXP3+ regulatory T cells (Tregs) and conventional T cells (Tcons) has been used as prevention of graft-versus-host disease (GVHD)...

Evaluating Fixed-Duration Ibrutinib and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia

A fixed-duration combination of the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the first-generation BCL2 inhibitor venetoclax appeared to be a...
Advertisement
Advertisement